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OBJECTIVES This study was undertaken to assess whether prodromal angina could have beneficial effects
in diabetic patients with acute myocardial infarction (AMI).
BACKGROUND Prodromal angina occurring shortly before the onset of AMI is associated with favorable
outcomes by the mechanism of ischemic preconditioning. However, little is known about the
impact of diabetes on ischemic preconditioning.
METHODS We studied 611 patients with a first anterior wall AMI who underwent emergency
catheterization within 12 h after the onset of chest pain: 490 patients without diabetes and
121 patients with non–insulin treated diabetes. Prodromal angina was defined as angina
episode(s) occurring within 24 h before the onset of AMI. Serial contrast left ventriculograms
were obtained in 424 patients at the time of acute and predischarge catheterization.
RESULTS In non-diabetic patients, prodromal angina was associated with lower peak creatine kinase
(CK) value (3,068 6 2,647 IU/l vs. 3,601 6 2,462 IU/l, p 5 0.037), larger increase in left
ventricular ejection fraction (LVEF) (10.1 6 13.0% vs. 5.8 6 13.4%, p 5 0.004) and lower
in-hospital mortality (3.4% vs. 9.3%, p 5 0.015). On the contrary, in diabetic patients, there
was no significant difference in peak CK value (3,382 6 2,520 IU/l vs. 3,233 6 2,412 IU/l,
p 5 NS), the change in LVEF (6.7 6 13.8% vs. 7.1 6 12.4%, p 5 NS) and in-hospital
mortality (8.8% vs. 11.0%, p 5 NS) between patients with and patients without prodromal
angina.
CONCLUSIONS Prodromal angina limited infarct size, enhanced recovery of LV function and improved
survival in non-diabetic patients with AMI. However, such beneficial effects of prodromal
angina were not observed in diabetic patients, suggesting that diabetes might prevent
ischemic preconditioning. (J Am Coll Cardiol 2001;38:1007–11) © 2001 by the American
College of Cardiology
Diabetes mellitus is a risk factor for morbidity and mortality
in acute myocardial infarction (AMI) (1–5). Although
diabetes is associated with comorbid risk factors, diabetes is
still an independent predictor of death after AMI. Angina
pectoris occurring shortly before the onset of AMI limits
infarct size, improves left ventricular (LV) function and
enhances survival (6–10). Transient ischemic episodes have
cardioprotective effects against subsequent ischemia, which
is called ischemic preconditioning (11). Some experimental
studies have reported that ischemic preconditioning is lost
in the presence of diabetes (12,13). Loss of ischemic
preconditioning may be responsible for the poor outcome of
diabetic patients with AMI. However, there is no clinical
data on the impact of diabetes on ischemic preconditioning
in patients with AMI. This study was undertaken to assess
the impact of diabetes on ischemic preconditioning in
patients with a first anterior wall AMI.
METHODS
Study patients. Between January 1981 and December
1999, 611 patients with a first anterior wall AMI underwent
coronary angiography within 12 h after the onset of chest
pain. Anterior wall AMI was diagnosed by chest pain
consistent with ongoing myocardial ischemia persisting
.30 min and at least 1-mm ST elevation in at least two
adjacent precordial electrocardiographic leads. Serum crea-
tine kinase (CK) was measured every 3 h for at least 24 h,
and peak CK value had to be more than twice the normal
upper limit. Nine patients with diabetes who had been
treated with insulin were excluded from this study.
Cardiac catheterization. Emergency cardiac catheteriza-
tion was performed via the right femoral artery or left
brachial artery approach after heparin administration. Se-
lective coronary angiography was performed in multiple
projections before the initiation of reperfusion therapy.
Immediately after diagnostic angiography, reperfusion ther-
apy was performed with coronary thrombolysis or angio-
plasty. The allocation of thrombolysis or angioplasty was
not randomized and was based on the physician’s decision.
In general, thrombolytic therapy was performed without
adjunctive angioplasty during the first four years. During the
From the Department of Cardiology, Hiroshima City Hospital, Hiroshima, Japan.
Manuscript received February 26, 2001; revised manuscript received May 22, 2001,
accepted June 14, 2001.
Journal of the American College of Cardiology Vol. 38, No. 4, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01477-2
next 10 years, conventional balloon angioplasty was per-
formed for severe stenosis after thrombolysis, after failed
thrombolysis or without thrombolytic therapy. Since 1994,
coronary stenting was performed if appropriate.
Angiographic analysis. All coronary angiograms were re-
viewed by two angiographers without knowledge of the
clinical variables. The perfusion status of the left anterior
descending artery was determined in accordance with the
Thrombolysis In Myocardial Infarction (TIMI) study clas-
sification (14). An occluded artery was defined as TIMI
flow grade 0 or 1. Reperfusion was defined as TIMI flow
grade 3. Initial TIMI flow grade was assessed before the
initiation of reperfusion therapy, and final TIMI flow grade
on the final shot of the angiography. Multivessel coronary
disease was defined as $75% stenosis in one or more vessels
remote from the infarct artery. Left main coronary disease of
$50% was considered to be at least two-vessel involvement.
The extent of collateral circulation was assessed on pretreat-
ment angiogram and classified in accordance with the
method described by Rentrop et al. (15). Collateral circu-
lation was considered to be present if the grade was $2.
Contrast left ventriculography was performed in the 30°
right anterior oblique projection before reperfusion therapy
and at the time of predischarge catheterization. The left
ventricular ejection fraction (LVEF) was calculated by
means of the area-length method.
Definition of prodromal angina. Data were collected on
the study form regarding whether patients ever experienced
angina before AMI. Prodromal angina was defined as
typical chest pain episode(s) persisting #30 min either at
rest or on effort within 24 h before the onset of AMI.
Patients with stable angina pectoris were also included if
they had chest pain episode(s) within 24 h before infarction.
Data analysis. Data were collected regarding whether pa-
tients had a previous or current diagnosis of diabetes
mellitus during hospitalization. Statistical analysis was per-
formed with the chi-square and t test. Differences were
considered significant if the p value was ,0.05. All group
data are expressed as mean 6 SD.
RESULTS
Baseline characteristics. There were 121 patients with
diabetes (20%): 68 patients were treated with diet alone, and
53 patients with oral hypoglycemic drugs. Prodromal angina
was found in 53 patients (44%) with diabetes and 147
patients (30%) without diabetes (p 5 0.004).
There was no significant difference in age, gender, hy-
pertension, Killip class upon admission, time to angiogra-
phy, initial patency of the infarct artery, multivessel disease,
collateral circulation, modality of reperfusion therapy and
final reperfusion between diabetic patients with and diabetic
patients without prodromal angina (Table 1). Also, there
was no significant difference in the clinical and angiographic
variables, except for more hypertension in non-diabetic
patients with, than in non-diabetic patients without, pro-
dromal angina (Table 2).
Outcomes of non-diabetic patients. In non-diabetic pa-
tients, peak CK value was obtained in 462 patients (94%).
Peak CK value was significantly lower in non-diabetic
patients with prodromal angina than it was in non-diabetic
patients without (3,068 6 2,647 IU/l vs. 3,601 6
2,462 IU/l, p 5 0.037; Fig. 1). Acute LVEF was obtained
before reperfusion therapy in 421 patients (86%) and was
not significantly different between non-diabetic patients
with and non-diabetic patients without prodromal angina
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CK 5 creatine kinase
TIMI 5 Thrombolysis In Myocardial Infarction
LVEF 5 left ventricular ejection fraction
Table 1. Characteristics in Non-Diabetic Patients With Versus Without Prodromal Angina
Prodromal Angina
p Value
Absent
(n 5 343)
Present
(n 5 147)
Age (yr, SD) 60 (12) 61 (11) 0.63 (NS)
Male gender (%) 275 (80%) 116 (79%) 0.75 (NS)
Hypertension (%) 214 (62%) 95 (65%) 0.64 (NS)
Killip class $2 (%) 45 (13%) 13 (9%) 0.17 (NS)
Time to angiography (h, SD) 4.0 (2.6) 4.1 (3.1) 0.78 (NS)
Initial TIMI flow grade $2 (%) 65 (19%) 35 (24%) 0.22 (NS)
Collateral circulation (%) 114 (33%) 49 (33%) 0.98 (NS)
Multivessel disease (%) 77 (22%) 38 (26%) 0.42 (NS)
Reperfusion therapy 0.31 (NS)
Angioplasty (%) 238 (70%) 109 (74%)
Thrombolysis (%)* 76 (22%) 21 (21%)
Bypass surgery (%) 3 (2%) 4 (3%)
None (%) 20 (6%) 3 (2%)
Final TIMI flow grade 3 (%)† 246 (74%) 113 (79%) 0.21 (NS)
*Thrombolysis without rescue or immediate angioplasty; †data were not obtained in patients undergoing bypass surgery.
TIMI 5 Thrombolysis In Myocardial Infarction.
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(49.6 6 11.5% vs. 47.5 6 11.1%, p 5 NS; Fig. 2). However,
predischarge LVEF, obtained in 385 patients (79%), was
significantly higher in non-diabetic patients with prodromal
angina than it was in non-diabetic patients without (59.1 6
14.1% vs. 53.2 6 14.9%, p , 0.001; Fig. 2). Serial left
ventriculograms were obtained in 348 patients (75%), and
the change in LVEF was significantly larger in non-diabetic
patients with prodromal angina than it was in non-diabetic
patients without (10.1 6 13.0% vs. 5.8 6 13.4%, p 5 0.004;
Fig. 2). In-hospital mortality was significantly lower in
non-diabetic patients with prodromal angina than it was in
non-diabetic patients without (3.4% vs. 9.3%, p 5 0.015;
Fig. 3).
Outcomes of diabetic patients. In diabetic patients, peak
CK value was obtained in 105 patients (87%) and was
similar between patients with and patients without prodro-
mal angina (3,461 6 2,581 IU/l vs. 3,240 6 2,459 IU/l, p 5
NS; Fig. 1). Acute LVEF, obtained in 92 patients (76%),
was not significantly different between diabetic patients
with, and diabetic patients without, prodromal angina
(46.1 6 12.6% vs. 49.0 6 11.9%, p 5 NS; Fig. 4).
Predischarge LVEF, obtained in 87 patients (72%), was not
significantly different between diabetic patients with pro-
dromal angina and diabetic patients without (53.0 6 15.3%
vs. 56.0 6 16.7%, p 5 NS; Fig. 4). The change in LVEF,
obtained in 76 patients (63%), was not significantly different
between diabetic patients with prodromal angina and dia-
betic patients without (6.7 6 13.8% vs. 7.1 6 12.4%, p 5
NS; Fig. 4). In-hospital mortality was not significantly
different between diabetic patients with prodromal angina
and diabetic patients without (9.4% vs. 11.8%, p 5 NS;
Fig. 3).
When only diabetic patients who had been treated
exclusively with diet were studied, there was no significant
difference in peak CK (3,586 6 2,709 IU/l vs. 3,550 6
2,821 IU/l, p 5 NS) and predischarge LVEF (55.1 6
15.7% vs. 56.8 6 19.8%, p 5 NS) between patients with
and patients without prodromal angina. Also, among dia-
betic patients treated with oral hypoglycemic drugs, there
Figure 1. Peak creatine kinase value was significantly smaller in non-
diabetic patients with prodromal angina (solid bars) than it was in
non-diabetic patients without (open bars). It was not significantly different
between diabetic patients with prodromal angina and diabetic patients
without.
Figure 2. Acute left ventricular ejection fraction (LVEF), predischarge
LVEF and the change in LVEF in non-diabetic patients with prodromal
angina (solid bars) and non-diabetic patients without (open bars). Acute
LVEF was not significantly different, but predischarge LVEF and the
change in LVEF were significantly better in non-diabetic patients with
prodromal angina than in non-diabetic patients without.
Table 2. Characteristics in Diabetic Patients With Versus Without Prodromal Angina
Prodromal Angina
p Value
Absent
(n 5 68)
Present
(n 5 53)
Age (yr, SD) 61 (11) 60 (10) 0.78 (NS)
Male gender (%) 54 (79%) 42 (79%) 0.98 (NS)
Hypertension (%) 37 (54%) 19 (36%) 0.04
Killip class $2 (%) 11 (16%) 11 (21%) 0.52 (NS)
Time to angiography (h, SD) 3.9 (2.3) 4.3 (3.1) 0.52 (NS)
Initial TIMI flow grade $2 (%) 14 (21%) 16 (30%) 0.23 (NS)
Collateral circulation (%) 26 (38%) 17 (32%) 0.48 (NS)
Multivessel disease (%) 32 (47%) 18 (34%) 0.15 (NS)
Reperfusion therapy 0.09 (NS)
Angioplasty (%) 40 (59%) 42 (79%)
Thrombolysis (%)* 19 (28%) 7 (13%)
Bypass surgery (%) 7 (10%) 2 (4%)
None (%) 2 (3%) 2 (4%)
Final TIMI flow grade 3 (%)† 44 (73%) 40 (78%) 0.53 (NS)
*Thrombolysis without rescue or immediate angioplasty; †data were not obtained in patients undergoing bypass surgery.
TIMI 5 Thrombolysis In Myocardial Infarction.
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was no significant difference in peak CK (3,289 6
2,446 IU/l vs. 2,843 6 1,882 IU/l, p 5 NS) and predis-
charge LVEF (50.7 6 14.9% vs. 55.2 6 13.0%, p 5 NS)
between patients with and patients without prodromal
angina. The difference in peak CK and predischarge LVEF
was not significant between diabetic patients treated with
diet only and diabetic patients treated with oral hypoglyce-
mic drugs.
DISCUSSION
Findings of this study. This study demonstrated that: 1)
prodromal angina limited infarct size, enhanced improve-
ment of LV function and improved in-hospital mortality in
non-diabetic patients with AMI, and 2) these beneficial
effects of prodromal angina were not obtained in non–
insulin treated diabetic patients. These results suggest that
ischemic preconditioning is prevented in diabetic patients
with AMI.
Diabetes and AMI. Diabetes mellitus is a risk factor not
only for the development of AMI but also for poor
outcomes after AMI. Previous studies in the reperfusion era
have demonstrated that the relative risk of mortality after
AMI was approximately 50% greater in diabetic patients
compared with non-diabetic patients (2–5). Although it has
been reported that diabetic patients have more co-morbid
risk factors including older age, more female gender, more
previous infarction and more severe coronary artery disease,
most studies have reported that diabetes is an independent
predictor for mortality after AMI.
Prodromal angina and ischemic preconditioning. Murry
et al. (11) first reported that brief episodes of ischemia in
dogs limited infarct size resulting from a subsequent coro-
nary occlusion and termed it “ischemic preconditioning.”
Since then, several clinical studies have demonstrated that
ischemic preconditioning occurs in patients with repetitive
balloon inflation during coronary angioplasty and with
intermittent aortic cross-clamping during coronary artery
bypass surgery (16,17). It has been demonstrated that
angina pectoris occurring shortly before the onset of AMI is
associated with favorable outcomes, including smaller in-
farct size, improved LV function and enhanced survival after
reperfusion therapy for AMI (6–10) and that angina epi-
sodes closest to the time of infarction have the most
benefits, suggesting a relationship to ischemic precondition-
ing (7). Kloner et al. (10), reviewing 3,002 patients enrolled
in the TIMI-9B study, have reported that the benefits of
pre-infarction angina on clinical events were manifest only
when the time between onset of angina and infarction was
within 24 h and that a history of any angina alone was not
associated with a reduced event rate. Thus, in the present
study we defined “prodromal angina” as angina occurring
#24 h before the onset of infarction.
Diabetes and ischemic preconditioning. Some previous
experimental studies have reported that diabetic hearts are
more sensitive to ischemic insults and that the cardio-
protective effects of ischemic preconditioning are lost,
but others have suggested that diabetic hearts are more
protective against ischemia than non-diabetic hearts
(12,13,18,19). The inconsistent results of these studies
might be due to the difference in experimental conditions. It
has been suggested that longer duration of diabetes, higher
plasma glucose level and the presence of residual flow during
ischemia were associated with the increased vulnerability of
diabetic hearts (13). Most clinical episodes of AMI in
diabetic patients occur in such conditions. Moreover, it has
been consistently demonstrated that diabetic patients have
poorer outcomes after AMI than non-diabetic patients.
This study is the first to report that the cardioprotective
effects of prodromal angina are lost in diabetic patients with
AMI. This loss of ischemic preconditioning may be, at least
in part, responsible for the poor outcomes of diabetic
patients with AMI.
Patients with diabetes, particularly older diabetic patients,
may present with more atypical features and may spend a
longer time getting to a hospital. Delay in treatment might
have affected the difference in outcomes. However, in the
present study, there was no difference in time from the onset
Figure 3. In-hospital mortality was significantly lower in non-diabetic
patients with prodromal angina (solid bars) than in non-diabetic patients
without (open bars). There was no significant difference in in-hospital
mortality between diabetic patients with, and diabetic patients without,
prodromal angina.
Figure 4. Acute left ventricular ejection fraction (LVEF), predischarge
LVEF and the change in LVEF in diabetic patients with prodromal angina
(solid bars) and in diabetic patients without (open bars). Acute LVEF,
predischarge LVEF and the change in LVEF were not significantly
different between diabetic patients with prodromal angina and diabetic
patients without.
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of chest pain to angiography between non-diabetic and
diabetic patients (4.0 6 2.8 h vs. 4.1 6 2.7 h, p 5 NS). To
clarify this issue, we performed additional analysis using
only patients who underwent angiography within 6 h after
the onset of chest pain, in which prodromal angina had
beneficial effects on outcomes in non-diabetic patients but
not in diabetic patients. Also, if only patients ,70 years old
were analyzed, results similar to those of the original
analysis were obtained (data not shown).
There are several possible mechanisms that may explain
the loss of ischemic preconditioning in diabetic hearts (20).
Ischemic preconditioning is mediated by activation of the
KATP channel. It has been reported that the nature of the
KATP channel is altered in diabetic hearts (21). Also, acute
hyperglycemia has been shown to abolish ischemic precon-
ditioning (22). In addition, oral hypoglycemic drugs inhibit
the KATP channel. Several previous studies have reported
that oral hypoglycemic drugs prevent ischemic precondi-
tioning and increase mortality after AMI (23,24). The loss
of the cardioprotective effects of prodromal angina may be,
in part, attributable to oral hypoglycemic drugs. However, it
is still noteworthy that the cardioprotective effects of pro-
dromal angina were lost even in patients with diabetes who
had been treated without oral hypoglycemic drugs.
Study limitations. This study suffers from the limitations
of all retrospective investigations. The allocation of reper-
fusion therapy was based on the physician’s decision. But
the modality of reperfusion therapy and the incidence of
reperfusion were similar between diabetic and non-diabetic
patients. A small sample size is another limitation of this
study. However, it is noteworthy that peak CK and predis-
charge LVEF were not only significantly different but also
tended to be worse in diabetic patients with prodromal
angina. There were only nine insulin-treated diabetic pa-
tients, and the impact of insulin-treated diabetes on isch-
emic preconditioning could not be discussed, because of its
small sample size. A patient was defined as having diabetes
if a physician had diagnosed diabetes before, or at the time
of, the current myocardial infarction. Because an oral
glucose tolerance test was not routinely performed, some
diabetic patients may not have been diagnosed as having
diabetes. However, in this study, the incidence of diabetes
was comparable with that of previous studies.
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